PHVS
Pharvaris N.V.
Price Chart
Latest Quote
$33.66
-1.50 (-4.27%)
Current Price
| Previous Close | $35.16 |
| Open | $35.06 |
| Day High | $35.18 |
| Day Low | $33.23 |
| Volume | 287,608 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 69.88M |
| Total Debt | $846K |
| Cash Equivalents | $282.66M |
| Net Income | $-192.93M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.44B |
| EPS (TTM) | $-3.10 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.04B |
| Income | $-192.93M |
| Book/sh | $4.14 |
| Cash/sh | $3.53 |
| Employees | 134 |
Financial Ratios
| Quick Ratio | 10.99 |
| Current Ratio | 11.24 |
| Debt/Eq | 0.31 |
Returns & Margins
| ROA | -42.31% |
| ROE | -73.02% |
Ownership
| Insider Ownership | 6.13% |
| Institutional Ownership | 85.30% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -12.49 |
| P/B | 8.43 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $47.31 |
Technical Indicators
| SMA20 | $34.24 |
| SMA50 | $32.03 |
| SMA200 | $27.43 |
| RSI | 54.65 |
| ATR | 1.6389 |
| Shares Float | 40.33M |
| Short Float | 1.71% |
| Short Ratio | 2.39 |
| Volatility | -2.34 |
| Rel Volume | 0.42 |
Performance History
| Week | -0.37% |
| Month | +11.06% |
| Quarter | +21.40% |
| 6 Months | +36.32% |
| YTD | +31.95% |
| Year | +51.91% |
| 3 Years | +125.42% |
| 5 Years | +134.18% |
| 10 Years | +20.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $34.94 | 236,400 |
| 2026-07-16 | $33.66 | 289,300 |
| 2026-07-15 | $35.16 | 234,400 |
| 2026-07-14 | $34.42 | 283,100 |
| 2026-07-13 | $35.07 | 286,700 |
| 2026-07-10 | $35.07 | 639,300 |
| 2026-07-09 | $35.96 | 1,887,300 |
| 2026-07-08 | $35.92 | 950,200 |
| 2026-07-07 | $34.59 | 972,700 |
| 2026-07-06 | $33.22 | 753,100 |
| 2026-07-02 | $33.86 | 478,100 |
| 2026-07-01 | $33.95 | 376,100 |
| 2026-06-30 | $34.58 | 1,030,800 |
| 2026-06-29 | $34.71 | 725,500 |
| 2026-06-26 | $34.01 | 519,300 |
| 2026-06-25 | $33.30 | 496,200 |
| 2026-06-24 | $33.29 | 419,500 |
| 2026-06-23 | $33.19 | 326,700 |
| 2026-06-22 | $33.00 | 304,100 |
| 2026-06-18 | $32.80 | 182,200 |
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
đ° Latest News
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy
Zacks âĸ 2026-07-15T16:00:03Z
IBM downgraded, Cava upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-07-15T13:33:32Z
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade
Zacks âĸ 2026-07-14T13:55:03Z
Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development
Investor's Business Daily âĸ 2026-07-06T20:33:55Z
What This Fundâs $14 Million Ocular Therapeutix Exit Could Signal for Investors
Motley Fool âĸ 2026-05-19T17:26:23Z
Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Case
Simply Wall St. âĸ 2026-05-14T06:13:17Z
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000
Motley Fool âĸ 2026-05-11T20:49:29Z
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
Motley Fool âĸ 2026-04-30T00:42:01Z
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
Investor's Business Daily âĸ 2026-04-29T20:03:45Z
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.
Motley Fool âĸ 2026-04-13T14:44:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $194,305,421 | $166,691,272 | $110,885,153 | $99,215,802 |
| Other Income Expense | $-11,728,546 | $9,003,563 | $-3,565,975 | $12,700,678 |
| Net Non Operating Interest Income Expense | $7,279,388 | $6,204,291 | $233,431 | $-44,913 |
| Total Other Finance Cost | $-7,279,388 | $-6,204,291 | $-233,431 | $44,913 |
| Operating Expense | $194,305,421 | $166,691,272 | $110,885,153 | $99,215,802 |
| General And Administrative Expense | $51,881,693 | $53,918,352 | $35,856,512 | $33,568,690 |
| Interest Expense | - | - | - | $18,427 |
| Interest Expense Non Operating | - | - | - | $18,427 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-201,029,065 | $-153,571,547 | $-115,417,702 | $-87,337,025 |
| Net Interest Income | $7,279,388 | $6,204,291 | $233,431 | $-44,913 |
| Normalized Income | $-192,326,484 | $-160,252,191 | $-112,771,749 | $-96,760,928 |
| Net Income From Continuing And Discontinued Operation | $-201,029,065 | $-153,571,547 | $-115,417,702 | $-87,337,025 |
| Net Income Common Stockholders | $-201,029,065 | $-153,571,547 | $-115,417,702 | $-87,337,025 |
| Net Income | $-201,029,065 | $-153,571,547 | $-115,417,702 | $-87,337,025 |
| Net Income Including Noncontrolling Interests | $-201,029,065 | $-153,571,547 | $-115,417,702 | $-87,337,025 |
| Net Income Continuous Operations | $-201,029,065 | $-153,571,547 | $-115,417,702 | $-87,337,025 |
| Pretax Income | $-198,754,579 | $-151,483,418 | $-114,217,696 | $-86,560,037 |
| Operating Income | $-194,305,421 | $-166,691,272 | $-110,885,153 | $-99,215,802 |
| Per Share | ||||
| Diluted EPS | $-3.40 | $-2.84 | $-3.01 | $-2.60 |
| Basic EPS | $-3.40 | $-2.84 | $-3.01 | $-2.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $-3,025,965 | $2,322,919 | $-920,022 | $3,276,775 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-182,098,210 | $-175,386,412 | $-107,024,497 | $-111,741,490 |
| Total Unusual Items | $-11,728,546 | $9,003,563 | $-3,565,975 | $12,700,678 |
| Total Unusual Items Excluding Goodwill | $-11,728,546 | $9,003,563 | $-3,565,975 | $12,700,678 |
| Reconciled Depreciation | $478,665 | $308,423 | $294,681 | $174,990 |
| EBITDA (Bullshit earnings) | $-193,826,756 | $-166,382,849 | $-110,590,472 | $-99,040,812 |
| EBIT | $-194,305,421 | $-166,691,272 | $-110,885,153 | $-99,215,802 |
| Diluted Average Shares | $67,687,928 | $61,808,411 | $43,926,379 | $38,427,892 |
| Basic Average Shares | $67,687,928 | $61,808,411 | $43,926,379 | $38,427,892 |
| Diluted NI Availto Com Stockholders | $-201,029,065 | $-153,571,547 | $-115,417,702 | $-87,337,025 |
| Tax Provision | $2,274,486 | $2,088,128 | $1,200,006 | $776,987 |
| Gain On Sale Of Security | $-11,728,546 | $9,003,563 | $-3,565,975 | $12,700,678 |
| Research And Development | $142,423,728 | $112,772,920 | $75,028,641 | $65,647,112 |
| Selling General And Administration | $51,881,693 | $53,918,352 | $35,856,512 | $33,568,690 |
| Other Gand A | $25,405,923 | $32,312,278 | $20,622,691 | $18,139,632 |
| Salaries And Wages | $26,475,770 | $21,606,074 | $15,233,821 | $15,429,058 |
| Insurance And Claims | - | - | $6,901,045 | $7,372,665 |
Fetched: 2026-07-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $310,382,544 | $306,362,415 | $439,414,664 | $170,776,928 |
| Total Assets | $344,914,199 | $333,380,750 | $456,172,173 | $191,914,175 |
| Total Non Current Assets | $2,616,445 | $2,237,058 | $964,645 | $1,014,007 |
| Non Current Deferred Assets | $1,015,277 | $542,731 | $443,397 | $297,257 |
| Non Current Deferred Taxes Assets | $1,015,277 | $542,731 | $443,397 | $297,257 |
| Current Assets | $342,297,753 | $331,143,691 | $455,207,527 | $190,900,168 |
| Prepaid Assets | $3,361,802 | $6,575,544 | $5,674,930 | $4,627,294 |
| Receivables | $5,207,235 | $3,369,009 | $1,188,815 | $437,606 |
| Taxes Receivable | $5,207,235 | $3,369,009 | $1,188,815 | $437,606 |
| Cash Cash Equivalents And Short Term Investments | $333,728,717 | $321,199,138 | $447,633,468 | $185,168,690 |
| Cash And Cash Equivalents | $333,728,717 | $321,199,138 | $447,633,468 | $185,168,690 |
| Other Current Assets | - | - | $710,315 | $666,578 |
| Accounts Receivable | - | - | - | $0 |
| Debt | ||||
| Total Debt | $888,785 | $985,664 | $273,347 | $499,796 |
| Long Term Debt And Capital Lease Obligation | $659,708 | $731,171 | $49,844 | $285,375 |
| Current Debt And Capital Lease Obligation | $229,077 | $254,493 | $223,502 | $214,421 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $34,531,655 | $27,018,335 | $16,757,509 | $21,137,247 |
| Total Non Current Liabilities Net Minority Interest | $659,708 | $731,171 | $49,844 | $285,375 |
| Current Liabilities | $33,871,946 | $26,287,165 | $16,707,664 | $20,851,871 |
| Payables And Accrued Expenses | $20,562,268 | $17,076,845 | $9,742,643 | $17,238,059 |
| Payables | $6,928,370 | $5,908,635 | $3,821,107 | $8,176,639 |
| Total Tax Payable | $1,076,898 | $687,926 | $491,902 | $1,335,485 |
| Accounts Payable | $5,851,472 | $5,220,710 | $3,329,205 | $6,841,154 |
| Other Non Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $310,382,544 | $306,362,415 | $439,414,664 | $170,776,928 |
| Total Equity Gross Minority Interest | $310,382,544 | $306,362,415 | $439,414,664 | $170,776,928 |
| Stockholders Equity | $310,382,544 | $306,362,415 | $439,414,664 | $170,776,928 |
| Gains Losses Not Affecting Retained Earnings | $57,775,710 | $45,593,627 | $31,899,557 | $23,126,716 |
| Other Equity Adjustments | $58,084,828 | $45,436,046 | $31,916,244 | $23,077,185 |
| Retained Earnings | $-663,153,693 | $-460,246,020 | $-304,254,734 | $-187,859,151 |
| Other | ||||
| Ordinary Shares Number | $74,611,662 | $62,219,099 | $59,828,620 | $38,691,602 |
| Share Issued | $74,611,662 | $62,219,099 | $59,828,620 | $38,691,602 |
| Tangible Book Value | $310,382,544 | $306,362,415 | $439,414,664 | $170,776,928 |
| Invested Capital | $310,382,544 | $306,362,415 | $439,414,664 | $170,776,928 |
| Working Capital | $308,425,807 | $304,856,527 | $438,499,863 | $170,048,297 |
| Capital Lease Obligations | $888,785 | $985,664 | $273,347 | $499,796 |
| Total Capitalization | $310,382,544 | $306,362,415 | $439,414,664 | $170,776,928 |
| Foreign Currency Translation Adjustments | $-309,118 | $157,581 | $-16,686 | $49,531 |
| Additional Paid In Capital | $906,807,127 | $713,548,515 | $704,590,398 | $330,866,370 |
| Capital Stock | $8,953,400 | $7,466,292 | $7,179,443 | $4,642,993 |
| Common Stock | $8,953,400 | $7,466,292 | $7,179,443 | $4,642,993 |
| Long Term Capital Lease Obligation | $659,708 | $731,171 | $49,844 | $285,375 |
| Current Capital Lease Obligation | $229,077 | $254,493 | $223,502 | $214,421 |
| Pensionand Other Post Retirement Benefit Plans Current | $13,080,601 | $8,955,826 | $6,741,519 | $3,399,391 |
| Current Accrued Expenses | $13,633,899 | $11,168,210 | $5,921,537 | $9,061,420 |
| Net PPE | $1,601,168 | $1,694,327 | $521,248 | $716,749 |
| Accumulated Depreciation | $-468,291 | $-251,872 | $-143,447 | $-74,973 |
| Gross PPE | $2,069,459 | $1,946,199 | $664,696 | $791,722 |
| Other Properties | $2,069,459 | $1,946,199 | $664,696 | $791,722 |
Fetched: 2026-07-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-157,023,178 | $-138,064,395 | $-106,566,453 | $-76,987,337 |
| Operating Activities | ||||
| Operating Cash Flow | $-156,834,827 | $-137,448,736 | $-106,463,497 | $-76,845,122 |
| Cash Flow From Continuing Operating Activities | $-156,834,827 | $-137,448,736 | $-106,463,497 | $-76,845,122 |
| Operating Gains Losses | $13,435,249 | $-8,385,627 | $3,197,294 | $-12,700,678 |
| Investing Activities | ||||
| Capital Expenditure | $-188,351 | $-615,659 | $-102,957 | $-142,215 |
| Investing Cash Flow | $-188,351 | $-615,659 | $-102,957 | $-142,215 |
| Cash Flow From Continuing Investing Activities | $-188,351 | $-615,659 | $-102,957 | $-142,215 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $196,496,171 | $2,567,748 | $392,347,058 | $10,995,269 |
| Financing Cash Flow | $183,761,127 | $3,062,420 | $372,303,217 | $9,897,447 |
| Cash Flow From Continuing Financing Activities | $183,761,127 | $3,062,420 | $372,303,217 | $9,897,447 |
| Net Other Financing Charges | $-12,484,457 | $677,346 | $-19,791,545 | $-961,064 |
| Net Common Stock Issuance | $196,496,171 | $2,567,748 | $392,347,058 | $10,995,269 |
| Common Stock Issuance | $196,496,171 | $2,567,748 | $392,347,058 | $10,995,269 |
| Other | ||||
| Repayment Of Debt | $-250,587 | $-182,674 | $-252,296 | $-136,759 |
| End Cash Position | $333,728,717 | $321,199,138 | $447,633,468 | $185,168,690 |
| Beginning Cash Position | $321,199,138 | $447,633,468 | $185,168,690 | $239,534,484 |
| Effect Of Exchange Rate Changes | $-14,208,370 | $8,567,646 | $-3,271,985 | $12,724,095 |
| Changes In Cash | $26,737,948 | $-135,001,975 | $265,736,763 | $-67,089,890 |
| Net Issuance Payments Of Debt | $-250,587 | $-182,674 | $-252,296 | $-136,759 |
| Net Long Term Debt Issuance | $-250,587 | $-182,674 | $-252,296 | $-136,759 |
| Long Term Debt Payments | $-250,587 | $-182,674 | $-252,296 | $-136,759 |
| Net PPE Purchase And Sale | $-188,351 | $-615,659 | $-102,957 | $-142,215 |
| Purchase Of PPE | $-188,351 | $-615,659 | $-102,957 | $-142,215 |
| Taxes Refund Paid | $-2,481,390 | $-3,166,187 | $-1,268,204 | $-209,181 |
| Interest Received Cfo | $469,971 | $6,198,048 | $271,215 | - |
| Change In Working Capital | $8,723,432 | $6,739,083 | $-6,707,843 | $9,584,554 |
| Change In Other Current Assets | $1,997,082 | $-156,011 | $-1,091,374 | $-2,873,085 |
| Change In Payables And Accrued Expense | $7,105,456 | $6,934,357 | $-5,569,500 | $12,094,238 |
| Change In Accrued Expense | $7,135,100 | $5,042,853 | $-796,056 | $7,625,719 |
| Change In Payable | $-29,644 | $1,891,505 | $-4,773,444 | $4,468,520 |
| Change In Receivables | $-379,106 | $-39,263 | $-46,969 | $363,400 |
| Other Non Cash Items | $-502,965 | $-6,204,291 | $-233,431 | $44,913 |
| Stock Based Compensation | $21,796,790 | $18,545,233 | $12,200,488 | $12,985,355 |
| Depreciation Amortization Depletion | $478,665 | $308,423 | $294,681 | $174,990 |
| Depreciation And Amortization | $478,665 | $308,423 | $294,681 | $174,990 |
| Depreciation | $478,665 | $308,423 | $294,681 | $174,990 |
| Net Foreign Currency Exchange Gain Loss | $13,435,249 | $-8,385,627 | $3,197,294 | $-12,700,678 |
| Net Income From Continuing Operations | $-198,754,579 | $-151,483,418 | $-114,217,696 | $-86,560,037 |
| Interest Paid Cfo | - | - | - | $-165,038 |
Fetched: 2026-07-17